We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with...
Watson Pharmaceuticals, Inc. is Now Actavis, Inc. /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-si...
Watson Confirms Opana® ER Patent Challenge /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt;...
Watson Acquires Uteron Pharma SA /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-fami...
Forest Laboratories, Inc. (FRX) recently announced the Canadian approval of its hypertension treatment, Bystolic (nebivolol). The company expects to launch Bystolic, a long-acting...
Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow is Another One's Joy Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow is Another One's...
Watson To Host 2013 Investor Meeting January 25 In New York /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li...
Forest Laboratories, Inc. (FRX) recently entered into a settlement agreement with Glenmark Pharmaceuticals Ltd., relating to its patent infringement litigation for Bystolic...
Investor apprehensions surrounding fourth-quarter earnings dragged benchmarks into negative territory on Monday. Indices declined after posting a strong rally in the previous week, during which...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions